Review Article
[Retracted] Effects and Safety of Sacubitril/Valsartan for Patients with Myocardial Infarction: A Systematic Review and Meta-Analysis
Table 1
Baseline characteristics of included studies.
| Author | Year | Disease | No. of exp. | No. of con. | Age of exp. | No. of con. | Sex of exp. (M/total) | Sex of con. (M/total) | Intervention (exp.) | Intervention (con.) |
| Chi Chen | 2021 | Acute myocardial infarction | 42 | 39 | 51.28 ± 6.27 | 51.3 ± 6.21 | 27/42 | 24/39 | Sacubitril/valsartan | Bisoprolol |
| Kieran F. Docherty | 2021 | Myocardial infarction | 47 | 46 | 61.8 ± 10.6 | 59.7 ± 10.1 | 42/47 | 43/46 | Sacubitril/valsartan | Valsartan |
| Ahmed Rwzq, MD. PHD. | 2020 | ST-segment elevation myocardial infarction | 100 | 100 | 52 ± 9.2 | 57 ± 11.6 | 86/100 | 88/100 | Sacubitril/valsartan | Ramipril |
| Haiyan Wang | 2020 | Acute anterior wall myocardial infarction | 68 | 69 | 59.13 ± 7.15 | 60.56 ± 7.62 | 52/68 | 54/69 | Sacubitril/valsartan | Enalapril |
| Yi Zhang | 2020 | ST-elevation myocardial infarction | 79 | 77 | 60.3 ± 11.7 | 60 ± 10.9 | 59/79 | 55/77 | Sacubitril/valsartan | ACEI |
|
|